The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium

IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Alzheimer's & dementia: the journal of the Alzheimer's Association (Impact Factor: 12.41). 07/2008; 4(4):255-64. DOI: 10.1016/j.jalz.2008.04.009
Source: PubMed


In North America, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has established a platform to track the brain changes of Alzheimer's disease. A pilot study has been carried out in Europe to test the feasibility of the adoption of the ADNI platform (pilot E-ADNI).
Seven academic sites of the European Alzheimer's Disease Consortium (EADC) enrolled 19 patients with mild cognitive impairment (MCI), 22 with AD, and 18 older healthy persons by using the ADNI clinical and neuropsychological battery. ADNI compliant magnetic resonance imaging (MRI) scans, cerebrospinal fluid, and blood samples were shipped to central repositories. Medial temporal atrophy (MTA) and white matter hyperintensities (WMH) were assessed by a single rater by using visual rating scales.
Recruitment rate was 3.5 subjects per month per site. The cognitive, behavioral, and neuropsychological features of the European subjects were very similar to their U.S. counterparts. Three-dimensional T1-weighted MRI sequences were successfully performed on all subjects, and cerebrospinal fluid samples were obtained from 77%, 68%, and 83% of AD patients, MCI patients, and controls, respectively. Mean MTA score showed a significant increase from controls (left, right: 0.4, 0.3) to MCI patients (0.9, 0.8) to AD patients (2.3, 2.0), whereas mean WMH score did not differ among the three diagnostic groups (between 0.7 and 0.9). The distribution of both MRI markers was comparable to matched US-ADNI subjects.
Academic EADC centers can adopt the ADNI platform to enroll MCI and AD patients and older controls with global cognitive and structural imaging features remarkably similar to those of the US-ADNI.

Download full-text


Available from: Giancarlo Zito,
  • Source
    • "From the complete ADNI dataset of 822 subjects at baseline, we selected individuals for the Scan/Repeat Test Group that had both valid entry images and processed images that passed automated quality control [16]. (iv) Finally, the fourth was the Scan/Rescan Test Group, which was obtained with permission from the multicentric Pilot European ADNI project [17]. It included data from three healthy volunteers acting as human quality control phantoms for the study. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinicians and researchers alike are in need of quantitative and robust measurement tools to assess medial temporal lobe atrophy (MTA) due to Alzheimer's disease (AD). We recently proposed a morphological metric, extracted from T1-weighted magnetic resonance images (MRI), to track and estimate MTA in cohorts of controls, AD, and mild cognitive impairment subjects, at high-risk of progression to dementia. In this paper, we investigated its reliability through analysis of within-session scan/repeat images and scan/rescans from large multicenter studies. In total, we used MRI data from 1051 subjects recruited at over 60 centers. We processed the data identically and calculated our metric for each individual, based on the concept of distance in a high-dimensional space of intensity and shape characteristics. Over 759 subjects, the scan/repeat change in the mean was 1.97% (SD: 21.2%). Over three subjects, the scan/rescan change in the mean was 0.89% (SD: 22.1%). At this level, the minimum trial size required to detect this difference is 68 individuals for both samples. Our scan/repeat and scan/rescan results demonstrate that our MTA assessment metric shows high reliability, a necessary component of validity.
    International Journal of Alzheimer's Disease 09/2012; 2012(1):979804. DOI:10.1155/2012/979804
  • Source
    • "Data for the last subject (validation subject) was obtained with permission from the pilot, multicentric European ADNI project [20] (E-ADNI). It consisted in a healthy volunteer that acted as human quality control phantoms and that was scanned three times at IRCCS Fatebenefratelli (scan; repeat scan, same session; rescan) on the same day. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We propose a novel morphological factor estimate from structural MRI for disease state evaluation. We tested this methodology in the context of Alzheimer's disease (AD) with 349 subjects. The method consisted in (a) creating a reference MRI feature eigenspace using intensity and local volume change data from 149 healthy, young subjects; (b) projecting MRI data from 75 probable AD, 76 controls (CTRL), and 49 Mild Cognitive Impairment (MCI) in that space; (c) extracting high-dimensional discriminant functions; (d) calculating a single morphological factor based on various models. We used this methodology in leave-one-out experiments to (1) confirm the superiority of an inverse-squared model over other approaches; (2) obtain accuracy estimates for the discrimination of probable AD from CTRL (90%) and the prediction of conversion of MCI subjects to probable AD (79.4%).
    International Journal of Alzheimer's Disease 06/2011; 2011(7):914085. DOI:10.4061/2011/914085
  • Source
    • "The global biomarker interest inspired in part by ADNI will assist in characterizing persons with a broader range of educational levels and ethnic backgrounds. Among these world-wide studies are the European ADNI (Buerger, et al., 2009; Frisoni, et al., 2008); the AddNeuroMed study (Lovestone, et al., 2009); the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Aging (Ellis, et al., 2009); the Swedish Brain Power Initiative; and similar studies in Japan, Korea, and China (Miller, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Alzheimer's Disease Neuroimaging Initiative (ADNI) is providing critical new information on biomarkers in cognitively normal elderly, persons with mild cognitive impairment (MCI), and patients with mild Alzheimer's disease (AD). The data provide insights into the progression of the pathology of AD over time, assist in understanding which biomarkers might be most useful in clinical trials, and facilitate development of disease-modifying treatments. ADNI results are intended to support new AD treatment development; this report considers how ADNI information can be integrated in AD drug development programs. Cerebrospinal fluid (CSF) amyloid beta protein (Abeta) measures can be used in Phase I studies to detect any short term effects on Abeta levels in the CSF. Phase II studies may benefit most from biomarker measures that can inform decisions about Phase III. CSF Abeta levels, CSF total tau and phospho-tau measures, fluorodeoxyglucose positron emission tomography (FDG PET), Pittsburgh Compound B (PIB) amyloid imaging, or magnetic resonance imaging (MRI) may be employed to select patients in enriched trials or as outcomes for specific disease-modifying interventions. Use of biomarkers may allow Phase II trials to be conducted more efficiently with smaller populations of patients or shorted treatment times. New drug applications (NDAs) may include biomarker outcomes of phase III trials. ADNI patients are highly educated and are nearly all of Caucasian ethnicity limiting the generalizability of the results to other populations commonly included in global clinical trials. ADNI has inspired or collaborates with biomarker investigations worldwide and together these studies will provide biomarker information that can reduce development times and costs, improve drug safety, optimize drug efficacy, and bring new treatments to patients with or at risk for AD.
    Neurobiology of aging 05/2010; 31(8):1481-92. DOI:10.1016/j.neurobiolaging.2010.03.016 · 5.01 Impact Factor
Show more